ProfileGDS5678 / 1452631_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 67% 70% 66% 68% 71% 72% 68% 68% 67% 70% 67% 70% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.342970
GSM967853U87-EV human glioblastoma xenograft - Control 24.0806567
GSM967854U87-EV human glioblastoma xenograft - Control 34.3354470
GSM967855U87-EV human glioblastoma xenograft - Control 43.9782666
GSM967856U87-EV human glioblastoma xenograft - Control 54.0973868
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4650671
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5198772
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2013168
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1308468
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0579767
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.390270
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0463367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3262370
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2379269